DUAVIVE (conjugated estrogens/bazedoxifene) is indicated in women with a uterus for the treatment of moderate to severe vasomotor symptoms associated with menopause.
DUAVIVE should not be taken with a progestin, additional estrogens or selective estrogen receptor modulators (SERMs) (see DOSAGE AND ADMINISTRATION, Dosing Considerations)
DUAVIVE has not been studied in women over 75 years of age, therefore DUAVIVE is not recommended for women over 75 years of age (see CLINICAL TRIALS, Geriatrics and ACTION AND CLINICAL PHARMACOLOGY, Special Populations and Conditions, Geriatrics).
DUAVIVE is not indicated for pediatric use.
*Contact Medical Information. 9AM-5PM ET Monday to Friday; excluding holidays.
Submit a medical question for Pfizer prescription products.
Contact Pfizer Safety to report an adverse event, side effect or concern about the quality of a Pfizer product:
1 866 723-7111.
To report an adverse event related to the Pfizer-BioNTech COVID-19 Vaccine, and you are not part of a clinical trial* for this product, click the link below to submit your information:
Pfizer Safety Reporting Site
*If you are involved in a clinical trial for this product, adverse events should be reported to your coordinating study site.
You may also contact the Canada Vigilance Program directly to report adverse events or product quality concerns at